Novartis, Amgen, And Banner Alzheimer's Institute Announced Discontinuation Investigation of The BACE1 Inhibitor CNP520 for Alzheimer’s Prevention

Novartis, Amgen, And Banner Alzheimer’s Institute Announced Discontinuation Investigation of The BACE1 Inhibitor CNP520 for Alzheimer’s Prevention

Novartis, Amgen, and Banner Alzheimer’s Institute announced that they would discontinue the investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase II/III research within the Alzheimer’s Prevention Initiative Generation Program. An evaluation of unblinded data during a daily pre-planned review identified worsening in […]

News Pharma